Zai LabZLAB +2.59%64 EV-to-EBIT is -9.81 as of Jul. 01, 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.27 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 368 Biotechnology companies, Zai Lab ranks worse than 271738.86% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Zai Lab's Enterprise Value is $1,707.0 Mil.
Zai Lab's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-173.9 Mil. Therefore, Zai Lab's EV-to-EBIT for today is -9.81.
The historical rank and industry rank for Zai Lab's EV-to-EBIT or its related term are showing as below:
ZLAB'
s EV-to-EBIT Range Over the Past 10 Years
Min: -55.35 Med: -10.11 Max: -2.08
Current: -9.81
During the past 11 years, the highest EV-to-EBIT of Zai Lab was -2.08. The lowest was -55.35. And the median was -10.11.
ZLAB's EV-to-EBIT is ranked worse than 100% of 368
companies
in the Biotechnology industry
Industry Median: 14.985
vs ZLAB: -9.81
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Zai Lab's Enterprise Value for the quarter that ended in Mar. 2026 was $1,658.9 Mil.
Zai Lab's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-173.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab EV-to-EBIT Related Terms
Zai Lab EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Zai Lab's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zai Lab's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zai Lab's EV-to-EBIT falls into.
Zai Lab's current Enterprise Value is $1,707.0 Mil.
Zai Lab's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-173.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (ZLAB) has a EV-to-EBIT of -9.81 as of Jul. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zai Lab and its competitors. According to the industry distribution chart, Zai Lab ranks #999999 out of 368 companies in the Biotechnology industry.
Is Zai Lab's EV-to-EBIT too high?
Zai Lab's current EV-to-EBIT is -9.81. Based on the distribution chart, Zai Lab ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's EV-to-EBIT compare to STOK and ADMA?
According to the Biotechnology industry distribution chart, Zai Lab ranks #999999 out of 368 companies for EV-to-EBIT. This places Zai Lab in the lower half of its industry. The industry median EV-to-EBIT is 14.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.99, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zai Lab and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current EV-to-EBIT is -9.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.27, compared to a current price of $19.49 — trading 35.6% below its estimated fair value. The current EV-to-EBIT is -9.81. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Zai Lab (ZLAB), the current EV-to-EBIT is -9.81 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $19.49 is trading 35.6% below its estimated GF Value™ of $30.27.
GuruFocus considers Zai Lab to be Possible Value Trap.
Key valuation signals for ZLAB:
EV-to-EBIT: -9.81
GF Value™: $30.27 vs. price of $19.49 (35.6% below fair value)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score
Get the complete analysis for ZLAB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 
